Platinum-based chemotherapy in childhood causes mutations that age liver cells

A study finds that cisplatin and carboplatin leave mutational signatures in children's livers that accelerate cellular ageing and may raise long-term cancer risk.

Published · AI-drafted summary based on 1 public source
Illustration for generic story
Illustrative image — not from the source article.
Share

Research published in late 2026 and reported by Stat News describes how platinum-based chemotherapy agents — cisplatin and carboplatin — leave persistent mutational signatures in the liver cells of children who receive them, causing those cells to take on characteristics more typical of adult liver tissue. The finding suggests that exposure to these drugs during childhood accelerates a form of hepatic cellular ageing.

The investigators found that treated children's liver cells more closely resembled adult cells in terms of their mutational and transcriptional profiles, a shift that may increase the long-term risk of secondary liver tumours. The study adds to a growing body of evidence examining the late effects of paediatric cancer treatment, which has become more pressing as survival rates for childhood cancers have improved significantly over recent decades.

The work does not overturn current treatment protocols, which rely on platinum compounds for a range of paediatric solid tumours and haematological malignancies. Rather, it characterises a biological mechanism underlying previously observed epidemiological signals of increased secondary cancer risk in childhood cancer survivors. Researchers say the findings may inform future monitoring strategies for this population, though any changes to clinical surveillance would depend on guidance from relevant professional bodies and regulatory authorities.

Plain-language version

For patients, families, and general readers. Educational only — not medical advice.

A new study has found that some chemotherapy medicines used to treat childhood cancers — called platinum-based drugs, including cisplatin and carboplatin — can leave lasting marks on the cells of the liver. These marks make the liver cells of treated children look more like those of adults, which researchers say could mean the cells have aged more quickly than usual. Scientists think this might be one reason why some childhood cancer survivors have a slightly higher chance of developing a new cancer later in life.

This is an early-stage finding that helps explain something scientists already suspected from looking at large groups of survivors over time. It does not mean that current treatments will stop, as these medicines save many lives. Researchers hope the discovery will eventually help doctors keep a better eye on people who had this type of chemotherapy as children.

This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.

Sources

Read the original reporting — these are the public sources this summary draws from.

  1. Primary source Stat News · 2026-09-10
    Platinum-based chemotherapy in childhood causes mutations that age the liver

Tags

platinum-chemotherapy paediatric-oncology liver-mutagenesis late-effects cancer-survivorship somatic-mutation childhood-cancer
Share

About Genetic Current

Educational summaries of public genetics news

Genetic Current is the news section of Evagene, an academic, research, and educational pedigree-modelling platform. Stories are AI-drafted summaries of items from trusted public sources, written for researchers, clinicians, educators, students, genealogists, and patients with an interest in genetics. Summaries are for educational and research purposes only and are not medical advice.

Join the Evagene Alpha Waiting List